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The efﬁcacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed
that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and
augment antitumoral CD8 T cells in the genital mucosa (GM) and increase regression of cervical cancer in an animal
model. Non muscle-invasive bladder cancer is another disease that is easily amenable to local therapies. In contrast to
data obtained in the GM, in this study we show that intravesical (IVES) instillation of synthetic toll-like receptor (TLR)
agonists only modestly induced recruitment of CD8 T cells to the bladder. However, IVES administration of Ty21a, a live
bacterial vaccine against typhoid fever, was much more effective and increased the number of total and vaccine-
speciﬁc CD8 T cells in the bladder approximately 10 fold. Comparison of chemokines induced in the bladder by either
CpG (a TLR-9 agonist) or Ty21a highlighted the preferential increase in complement component 5a, CXCL5, CXCL2,
CCL8, and CCL5 by Ty21a, suggesting their involvement in the attraction of T cells to the bladder. IVES treatment with
Ty21a after vaccination also signiﬁcantly increased tumor regression compared to vaccination alone, resulting in 90%
survival in an orthotopic murine model of bladder cancer expressing a prototype tumor antigen. Our data demonstrate
that combining vaccination with local immunostimulation may be an effective treatment strategy for different types of
cancer and also highlight the great potential of the Ty21a vaccine, which is routinely used worldwide, in such
combinatorial therapies.
Introduction
Although cancer vaccines have been considered a promis-
ing therapeutic approach, their general lack of clinical efficacy
as a single therapy argues for the use of combinatorial proto-
cols. Even when antitumor T cells are generated, trafficking
to the tumor site may be limited.1 This can be improved by
using appropriate vaccine administration routes, allowing tar-
geting of relevant tumor sites through specific mucosal hom-
ing or cancer site retention programs.2-5 An alternative
approach, irrespective of the immunization route, is to
enhance T-cell attraction to the tumor site through the local
application of selected chemokines6 or Toll-like receptor
(TLR) agonists that are able to modify the expression of
selectins, integrins, chemokines, and chemokine receptors.7,8
Along this line, we recently reported that intravaginal
(IVAG) administration of CpG (a TLR-9 agonist) resulted in
the accumulation of CD8 T cells co-expressing CCR5 and
CXCR3 chemokine receptors and E-selectin ligands (ESL),
most probably through CpG-induced expression of CCL5,
CXCL9, CXCL10, CXCL11, and/or E-selectin9. Most
importantly, in a murine model of cervical cancer, this strat-
egy resulted in more efficient genital tumor regression than
vaccination alone.9 Moreover, we have also shown that live
bacteria, such as Salmonella attenuated vaccine strains, are
more potent immunostimulants than CpG for the recruit-
ment of vaccine-specific CD8 T cells to the genital mucosa
(GM) of mice.10
Here, we explore how such therapeutic approaches can be
extended to other cancers. Bladder cancer is a common uro-
logic malignancy that is in part caused by smoking habits
and exposure to industrial chemicals and has an increased
incidence in the elderly population.11 Seventy percent of
bladder cancers are diagnosed as non muscle-invasive and are
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treated by transurethral resection (TUR). However, they have
a high propensity to recur and/or progress to invasive cancer.
Interestingly, the association between tuberculosis and a lower
frequency of cancer has led to use of the Bacillus Calmette
Guerin (BCG) vaccine against tuberculosis as a standard
intravesical (IVES) treatment after TUR for high-risk non
muscle-invasive bladder cancer (NMIBC) to reduce both
recurrence and progression.12,13 Repeated BCG treatments
are however associated with significant side effects and treat-
ment resistance, arguing for alternative or complementary
therapies such as vaccination.14 In the absence of a murine
bladder tumor model expressing a tumor antigen relevant in
humans, we have used an orthotopic model expressing E7 as
a prototype tumor antigen and a cognate E7 vaccine3 to
explore the ability of either synthetic or bacterial IVES TLR
agonists to increase CD8 T-cell recruitment to the bladder
and improve bladder tumor regression.
Results
IVES instillation of CpG after subcutaneous E7 vaccination
modestly increased the number of total and vaccine-specific
CD8 T cells in the bladder but did not influence bladder tumor
regression
Groups of C57BL/6 mice were subcutaneously (s.c.) immu-
nized with a long synthetic E7 peptide together with adjuvants15
or additionally received an IVES instillation of CpG 5 d after
immunization. Flow cytometric analysis of bladder cell suspen-
sions at day 9 showed a significant (approximately 2-fold)
increase in both total and vaccine-specific (TetE7C) CD8 T cells,
but not in CD4 T cells (Fig. 1A), compared to the group that
did not receive IVES CpG instillation. In contrast, systemic T
cell levels were not affected (Table 1). IFN-g ELISPOT analysis
confirmed the significant increase induced by IVES CpG (13 §
2 [geometric mean § standard error of the mean] IFN-g secret-
ing CD8 T cells/105 bladder cells, compared to 5 § 1 in the
absence of IVES immunostimulation, P < 0.01, Fig. 1B). This
increase is, however, modest compared to the 5-fold increase we
previously reported after IVAG CpG.9 Furthermore, and in con-
trast to the data obtained in the GM,9 successive IVES applica-
tions of CpG (days 6, 9, and 12) were not able to sustain a
higher vaccine-specific CD8 T-cell response in the bladder (see
day 15 in Fig. 1B). We further tested whether successive IVES
CpG instillations after vaccination would enhance the regression
of bladder tumors. For this purpose, mice were first IVES
instilled with E7- and luciferase-expressing tumor cells (TC-1
luc) and at day 8, when bioluminescent tumors were detected,
treated with vaccination alone or vaccination followed by IVES
CpG treatment (3 doses at 5, 8 and 11 d after vaccination). IVES
CpG alone had no effect on tumor regression compared to
untreated mice. As expected, vaccination resulted in significant
tumor regression and survival of 70% of the mice (P < 0.001),
although no benefit of the additional IVES CpG treatment was
observed (Fig. 1C).
Immunostimulation by IVES Ty21a live bacteria after
vaccination greatly increased the number of total and vaccine-
specific CD8 T cells in bladder
As the bladder may be more responsive to other TLR agonists,
we decided to test the effects of a synthetic TLR-3 agonist, poly
(I:C) (PIC), and 2 bacterial vaccines (BCG, which is used in
NMIBC immunotherapy, and Ty21a, the live attenuated Salmo-
nella enterica serovar Typhi vaccine against typhoid fever), as we
had previously shown that IVAG-attenuated Salmonella strains
increased the number of effector vaccine-specific CD8 T cells in
the GM.10 Groups of E7-vaccinated mice received IVES PIC,
BCG, or Ty21a 5 d after vaccination. IFN-g ELISPOT analysis
of bladder cell suspensions (Fig. 2) showed a significant (4- to 5-
fold) increase in vaccine-specific effector CD8 T-cells following
treatment with PIC (20 § 4 IFN-g–secreting CD8 T cells/105
bladder cells) and BCG (15 § 5) compared to vaccination alone
(4 § 1, P < 0.01 and P < 0.05, respectively). Interestingly, how-
ever, Ty21a bacteria resulted in a greater than 10-fold increase in
the number of vaccine-specific effector CD8 T cells in bladder
(58 § 9 IFN-g–secreting CD8 T cells/105 bladder cells; P <
0.0001). Live Ty21a bacteria were required as heat-killed Ty21a
bacteria were less efficient (24 § 3 IFN-g–secreting CD8 T cells/
105 bladder cells Fig. 2, P < 0.01 by Student t test). Flow cyto-
metric analysis of IVES Ty21a paralleled the ELISPOT data
with an approximately 10-fold increase in both total and vaccine-
specific CD8 T-cells (P < 0.001), confirming that the increase in
IFN-g–secreting cells measured by ELISPOT corresponded to
enhanced recruitment of CD8 T cells (Fig. 3A).
IVES Ty21a in the absence of vaccination induced an approx-
imately 4-fold increase in total CD8 T cells in the bladder. Inter-
estingly, a synergistic effect was observed between local
immunostimulation and systemic vaccination with respect to the
local recruitment of CD8 T cells; vaccination alone augmented
the total number of CD8 T cells in the bladder approximately
3-fold, whereas combination with IVES Ty21a resulted in a
40-fold increase (mean of »2% of total CD8 T cells compared
to 0.05% in na€ıve bladder). In contrast to CpG and PIC,9 IVES
Ty21a also induced a modest 3-fold increase in CD4 T-cells,
either alone or following vaccination (Fig. 3A), but once again
IVES immunostimulation had no systemic effect (Table 1). The
increased number of vaccine-specific effector CD8 T cells in
bladder was maintained at least until day 15 after a single IVES
Ty21a dose (49 § 8/105 bladder cells at day 9, compared to
55 § 10 at day 15) and successive IVES Ty21 resulted in a simi-
lar outcome (see Fig. 3B).
IVES Ty21a immunostimulation preferentially induced
C5a, CXCL5, CXCL2, CCL8, and CCL5
CD8 T cells accumulating in the GM upon IVAG CpG treat-
ment were shown to co-express CXCR3 and CCR5 as well as
ESL.9 We first examined the levels of these chemokine receptors
and ESL on the T cells that were attracted to the bladder upon
IVES CpG or Ty21a (Fig. 4). Our data show that ESL was
expressed on approximately 40% and 20% of CD4 and CD8 T
cells in the bladder, respectively, and that both frequencies were
significantly increased to 50–60% by IVES CpG or IVES Ty21a,
e1016697-2 Volume 4 Issue 7OncoImmunology
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suggesting that E-selectin may not be involved in preferential
recruitment of CD8 T cells versus CD4 T cells by either IVES
CpG or Ty21a in the bladder. CCR5 and CXCR3 were
expressed on less than 25% of the CD4 T cells and were not sig-
nificantly affected by IVES CpG or Ty21a. These chemokine
receptors were expressed by approximately 40% of the CD8 T
cells, with a slightly increased frequency after IVES CpG
although this was not significant (40–55% for CCR5 and
45–55% for CXCR3) and was not affected by Ty21a. In all cases,
less than 10% of the CD4 T cells co-expressed CCR5 and
CXCR3, whereas IVES CpG slightly increased the frequency of
CCR5CCXCR3CCD8 T cells (37% compared to 27% in unsti-
mulated or IVES Ty21-treated bladder), which may account for
the modest recruitment of CD8 T cells upon IVES CpG
(Fig. 1B). This suggests that some CXCR3/CCR5 ligand che-
mokines (CCL5, CXCL9, CXCL10, and/or CXCL11) may be
Figure 1. IVES CpG after E7 immunization modestly increased the number of E7-speciﬁc and total CD8 T cells in bladder but did not inﬂuence bladder
tumor regression. Groups of female C57BL/6 mice were immunized s.c. with the E7 vaccine. Five days later, mice were either left untreated (f, white dia-
mond) or received IVES with 1 (day 6, black square) or 3 (day 6, 9 and 12, white square) instillations of 100 mg CpG. Bladder cell suspensions were pre-
pared 3 d after the last IVES CpG and analyzed by ﬂow cytometry (A) or by IFN-g ELISPOT assay (B). Representative ﬂow cytometric analysis of bladder
cells is shown in the upper panel of (A) and the percentage of TetE7CCD8C T cells/total cells is indicated in parentheses. Horizontal bars represent
mean percent in panel (A) and geometric mean percent in panel (B). Signiﬁcant differences between groups of mice are indicated by *P < 0.05 and ** P
< 0.01. Two groups of tumor-bearing mice were left untreated (black triangles) or received IVES CpG (black asterisk), while 2 other groups received s.c.
E7 vaccine alone (white diamonds) or followed by IVES CpG (black square) (C). Signiﬁcant differences in mouse survival between each treatment and
control are indicated by ** P D 0.0012 and *** P D 0.0003 following an adjusted log-rank test.
www.tandfonline.com e1016697-3OncoImmunology
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induced by CpG. Knowledge of chemokine levels in the bladder
is limited to chemokine expression data obtained upon repeated
IVES instillation of BCG or lactobacillus16 or upon IVES instil-
lation of lipopolysaccharide.17 To gain more insight, we used a
chemokine protein array to determine the levels of 25 mouse che-
mokines 24 h after IVES instillation of phosphate buffered saline
(PBS), CpG, or Ty21a (see Table 2). All tested chemokines
could be detected in the bladder at variable levels over back-
ground (mean § SD, 8.3 § 3 pixels in PBS control animals).
Interestingly, all of the ligands of CXCR3 and CCR5 were
detected at low levels (9 to 12 pixels), with only CXCL10 being
increased by IVES CpG (1.8-fold) but not by Ty21a, which is in
agreement with the above findings. In addition, CCL6 and
CCL9/10 were similarly induced by CpG and Ty21a (1.5- and
4- to 5-fold, respectively), suggesting that these chemokines are
not involved in the specific recruitment of CD8 T cells upon
IVES Ty21a. In contrast, complement component 5/5a (C5a),
CXCL5, and CXCL2a were preferentially increased following
Ty21a immunostimulation (1.4- to 2-fold). When considering
the effect of IVES Ty21a on vaccination, comparison of the che-
mokine levels (Table 3) confirmed an increase in C5a and
CXCL5 by IVES Ty21a, and also showed an increase in CCL8
and CCL5 (1.5- to 1.7-fold). We therefore examined the expres-
sion of receptors of C5a (C5aR), CXCL5 and CXCL2
(CXCR2), CCL8 and CCL5 (CCR1, Fig. 4 for CCR5) on CD4
and CD8 T cells in the bladder (Table 4). Our data show that
fewer than 10% of either CD4 or CD8 T cells expressed these
receptors; this proportion decreased upon IVES Ty21a with the
exception of the percentage of C5aR-expressing CD4 T cells,
which increased non-significantly (~2-fold) to 35%. This suggests
that the chemokines that are increased by IVES Ty21a may not
directly mediate preferential attraction of CD8 T cells to the
bladder.
IVES Ty21a immunostimulation after vaccination
significantly improved bladder tumor regression and mouse
survival
Finally, we evaluated the therapeutic impact of IVES Ty21a
immunostimulation on bladder tumor regression. In the first
experiment, groups of 10 bladder tumor-bearing mice received 3
consecutive IVES Ty21a doses at days 13, 16, and 19 alone or
after vaccination (day 8), vaccination alone, or were left untreated
(Fig. 5A). Our data show that both vaccination alone and the
combinatorial treatment were significantly effective, resulting in
60% and 90% survival respectively (P < 0.01 compared to
untreated mice, adjusted log-rank test). In contrast, IVES Ty21a
treatment alone was not significantly effective. Because our ELI-
SPOT data showed similar vaccine-specific CD8 T cell recruit-
ment upon a single IVES Ty21a administration, we further
tested this protocol in a second experiment. Interestingly, the
results roughly paralleled the previous experiment, resulting in
60% survival after vaccination alone and 90% survival with the
combinatorial treatment (Fig. 5B), confirming that a single
IVES Ty21a immunostimulation after vaccination is sufficient to
increase antitumor T cells locally and provide almost full tumor
regression. Importantly, our data show that, irrespective of the
number of doses of IVES Ty21a used, the combinatorial treat-
ment was significantly more efficient than vaccination alone (P <
0.05 by Chi square test, Fig. 5C).
Discussion
Despite intensive research, immunotherapy of cancer remains
highly challenging and combination approaches are becoming
more and more appealing to improve clinical outcomes. Using a
preclinical model of bladder cancer, we show that IVES
Table 1. CD8 T-cell responses in the spleen of E7-vaccinated mice after chal-
lenge with different IVES immunostimulants
Ives immunostimulants % of total CD8a % of TetE7CCD8a
None (n D 7) 14.0 § 1.6 0.50 § 0.12
CpG (nD 4) 10.7 § 0.5 0.25 § 0.03
PIC (nD 4) 15.9 § 0.6 0.64 § 0.23
BCG (nD 5) 11.9 § 0.6 0.57 § 0.13
Ty21a (n D 6) 12.6 § 1.2 0.82 § 0.19
Ty21a HKb (nD 3) 14.1 § 0.5 0.72 § 0.16
amean § SEM; bheat-killed.
Figure 2. Increase in E7-speciﬁc IFN-g–secreting cells in the bladder by
different IVES immunostimulants after E7 immunization. Groups of
female C57BL/6 mice were immunized s.c. with the E7 vaccine. Five days
later, mice were either left untreated (f, white diamond) or received
IVES PIC (black circles), BCG (black triangles), live Ty21a (black squares),
or heat-killed Ty21a (white squares). After a further 3 days, bladder cell
suspensions were prepared and analyzed by IFN-g ELISPOT assay. Hori-
zontal bars represent geometric mean percent. Signiﬁcant differences
from control mice are indicated by *P < 0.05, **P < 0.01, or ****P <
0.0001.
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immunostimulation with Ty21a bacteria, but not CpG, after
tumor antigen vaccination efficiently recruits vaccine-specific
CD8 T cells to the bladder, resulting in tumor regression and
90% survival of the mice.
In contrast to the GM, the bladder turned out to be less
responsive to the synthetic TLR-9 agonist CpG, at least in terms
of induction of chemokines. The modest effect observed on CD8
T-cell recruitment to the bladder was associated with the
induction of fewer and different chemokines by CpG in the blad-
der (1.5- to 4-fold increase in CCL6, CCL9/10, and CXCL10)
compared to the GM, in which 10- to 70-fold increases in
CCL2, CCL3, CCL4, CXCL2, and CXCL10 were observed
24 h after IVAG CpG18 whereas CCL9 and CCL6 were not
affected or only poorly induced (1.6-fold at the RNA level for
CCL619). In contrast to CXCL10, which may be involved in the
recruitment of CXCR3-expressing CD8 T cells, CCL6 and
Figure 3. IVES Ty21a after E7 immunization strongly increased the number of T cells in bladder. Groups of na€ıve (white symbols) or s.c. E7-immunized
(black symbols) female C57BL/6 mice received IVES Ty21a 5 days after vaccination in 1 (day 6, black square) or 3 (day 6, 9, and 12, black circles) instilla-
tions, or were left untreated (f, diamonds). Bladder cell suspensions prepared 3 d after the last treatment were analyzed by ﬂow cytometry (A) or by
IFN-g ELISPOT (B) assay. A representative ﬂow cytometric analysis of bladder cells from vaccinated mice is shown in (A) (upper panel) and the percentage
of TetE7CCD8C T cells is indicated in parentheses. Horizontal bars represent geometric mean percent. Signiﬁcant differences between groups of mice
are indicated by *P < 0.05 or **P < 0.01, ***P < 0.001, or ****P < 0.0001.
www.tandfonline.com e1016697-5OncoImmunology
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CCL9 may attract CCR1-expressing macrophages or dendritic
cells as shown in the inflamed lung20 or in the bladder upon
IVES BCG treatment.16 This may account for the vaccination-
unrelated tumor regression induced by IVES CpG or BCG in
the MB49-bladder tumor model,21 as well as by Ty21a (our
unpublished data), which also induced CCL6 and CCL9
(Table 2). In turn, and in comparison to CpG, Ty21a uniquely
induced C5a, CXCL5, and CXCL2, whereas CCL8 and CCL5
are further induced following vaccination. C5a (through the
C5aR receptor) and CXCL5/CXCL2 (through the CXCR2
receptor) are primarily chemoattractants for neutrophils,22,23
although they are also involved in T-cell migration to the intesti-
nal mucosa24 and to the brain,25,26 whereas CCL5 and CCL8
can attract monocytes, NK cells, and activated T cells (through
CCR5 and CCR1 receptors).27-29 However, our data show a
lower or similar percentage of C5aR-, CXCR2-, CCR1-, and
CCR5-expressing CD8 T cells in the bladder with or without
IVES Ty21a immunostimulation, suggesting an indirect effect of
the cognate chemokines on the preferential increase in CD8 T
cells in the bladder.
Bacteria were recognized as poten-
tial immunotherapeutic treatments
against cancer more than 100 years
ago by William Coley.30 Later, the
association between tuberculosis and a
lower frequency of cancer led to use
of the BCG vaccine against tuberculo-
sis as a standard IVES treatment for
NMIBC.13 In our setting, we showed
that IVES BCG after vaccination also
increased the number of effector vac-
cine-specific CD8 T cells in the blad-
der, which prompted us to design a
clinical trial in which vaccination with
a tumor vaccine and IVES BCG are
combined (NCT01498172 in Clini-
calTrials.gov). This currently ongoing
trial is aimed to assess the safety of
the therapeutic combination as well as
potential enhancement of innate and/
or vaccine-specific T-cell responses
both systemically and locally in the
bladder. Our present findings, however,
demonstrate the superior efficacy of
Ty21a bacteria as an IVES immunosti-
mulant. Both BCG, which are gram-
positive bacteria, and Salmonella, which
are gram-negative bacteria, can provide
TLR-431,32 and TLR-933,34 agonists.
BCG also contains an agonist of TLR-
2, whereas Salmonella may engage
TLR-5 through flagellin.35 Interest-
ingly, mucosal application of Salmonella
flagellin induced CXCL2 in the lung,36
suggesting that the increase in CXCL2
observed in the bladder upon IVES
Ty21a may be mediated by TLR-5. In addition to TLR, it is
noteworthy that Salmonellae enterica encode 2 type 3 secretion
systems that allow the secretion of effector proteins able to trig-
ger proinflammatory host responses and their injection into
host cells.37 It is possible that this secretion system may also
contribute to T-cell recruitment in the bladder since live Ty21a
were more efficient than heat-killed bacteria, although the TLR-
agonist activities of the latter should be similar, or even
increased in the case of flagellin.38
NMIBC is the most prevalent form of bladder cancer, which
in turn represents the second most common urogenital cancer
with a lifetime risk of 1 in 26 for men and 1 in 87 for women in
the United States. The high recurrence/progression rate of
NMIBC contributes considerably to the high socioeconomic
burden associated with the management of these patients.39
Ty21a is a vaccine strain against typhoid fever (Vivotif!) that has
been used for decades by the oral route with an excellent safety
record40 and deserves investigation in NMIBC patients. Our
data suggest that this vaccine should be added to the list of TLR
agonists to be tested in oncologic indications.41
Figure 4. Expression of chemokine receptors and ESL on T cells from bladder upon IVES immunosti-
mulation. Groups of female C57BL/6 mice were immunized s.c. with the E7 vaccine. Five days later,
mice were either left untreated (circles) or received IVES CpG (triangles) or Ty21a (squares).
Bladder cell suspensions prepared 3 d after immunostimulation were analyzed by ﬂow cytometry.
Expression of chemokines and ESL among CD4 T cells (black symbols) or among CD8 T cells
(white symbols) is shown. ND: not detectable. Horizontal bars represent geometric mean percent. Sig-
niﬁcant differences versus control mice are indicated by **P < 0.01, ***P < 0.001, or
****P < 0.0001.
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Materials and Methods
Immunization and IVES immunostimulation of mice
C57BL/6 wild-type female mice aged 7 to 10 weeks
(Charles River) were used in compliance with ethical direc-
tives of the Swiss veterinary authorities. The E734–98 and
E749–57 peptides were chemically synthesized by the Protein
and Peptide Chemistry Facility of the Institute of Biochemis-
try (UNIL, Lausanne, Switzerland). Mice were immunized s.
c. with the E7 vaccine42 (50 mg E734-98, 0.4 mg Heat Labile
enterotoxin, kindly provided by Berna-Biotech, Bern,
Switzerland and 10 mg CpG, [#1826; 50-TCCATGACGT
TCCTGACGTT-30, Coley Pharmaceutical Group]). IVES
immunostimulation was performed by urethral catheterization
of deeply anesthetized mice using Introcan 24G/3/4 (Braun,
Melsungen, Germany) and instillation of 50 mL/mouse of
100 mg CpG, 100 mg PIC (Sigma-Aldrich or Invivogen),
2–8 £ 107CFU of BCG (OncoTICE), 1–5 £ 108 CFU of
attenuated Salmonella enterica serovar Typhi Ty21a bacteria43
(Berna-Biotech) grown to mid-log phase (OD600 < 0.7) in
Luria-Bertani broth (Difco BD).44
Table 2 Chemokine levels in bladder tissue upon IVES immunostimulation
Chemokine PBSa CpG (fold changeb) Ty21a (fold change)
CCL21 13.7 0.7 0.8
CXCL13 9.7 0.9 0.9
CCL6 49.5 1.5 1.4
C5/C5a 11.3 0.9 1.6
CCL28 9.2 0.9 1.0
Chemerin 24.5 0.9 1.0
CCL27 16.5 0.6 0.8
CXCL16 12.5 0.8 1.0
CCL11 12.1 0.7 0.9
CX3CL1 13.1 0.7 0.7
IL-16 51.6 0.5 0.6
CXCL10 10.9 1.8 1.0
CXCL11 10.4 0.8 1.0
CCL2 38.7 0.7 0.9
CXCL1 28.1 0.7 1.0
CXCL5 9.9 0.9 2.0
CCL8 12.0 1.0 1.1
CCL12 52.3 0.6 0.7
CCL22 15.4 0.6 0.7
CXCL9 12.3 0.7 0.8
CCL3/CCL4 10.0 0.9 1.0
CCL9/10 12.2 4.0 5.4
CXCL2 9.3 0.9 1.4
CCL5 9.3 0.9 1.2
CXCL12 15.3 0.8 0.8
aChemokine levels are expressed as mean pixel density, all are signiﬁcantly
higher than background signal C 3SD.
bRelative change in chemokine levels between immunostimulant and PBS.
Increased chemokine levels between immunostimulants and PBS ! 1.4-fold
are indicated in bold.
Table 3 Chemokine levels in bladder tissue upon vaccination and IVES
immunostimulation
Chemokine E7 vaccinea E7CTy21a (fold changeb)
CCL21 11.1 0.8
CXCL13 6.4 1.1
CCL6 52.1 1.2
C5/C5a 9.7 1.6
CCL28 6.1 0.9
Chemerin 40.8 0.7
CCL27 12.2 1.0
CXCL16 9.0 1.2
CCL11 6.9 1.1
CX3CL1 8.3 1.0
IL-16 35.7 0.9
CXCL10 11.5 1.2
CXCL11 7.7 1.0
CCL2 41.3 0.9
CXCL1 18.1 1.0
CXCL5 5.8 1.7
CCL8 14.0 1.5
CCL12 40.5 1.0
CCL22 9.2 0.9
CXCL9 8.4 0.9
CCL3/CCL4 6.2 1.0
CCL9/10 20.5 3.3
CXCL2 4.9 1.2
CCL5 5.5 1.7
CXCL12 24.7 0.9
aChemokine levels are expressed as mean pixel density; all are signiﬁcantly
higher than background signalC 3SD.
bRelative change in chemokine levels between vaccinated mice with and
without IVES Ty21a. Increased chemokine levels between vaccinated mice
with and without IVES Ty21a ! 1.5-fold are indicated in bold.
Table 4 T cells expressing the indicated chemokine receptor in the bladder of E7-vaccinated mice that were IVES challenged with Ty21a
% of total CD4Ca % of total CD8Ca
Immunostimulant IVES
Chemokine receptor None Ty21a None Ty21a
C5aR (n D 8b) 16.6 § 2.6 34.6 § 5.5 3.3 § 0.4 8.1 § 1.3
CXCR2 (n D 8b) 10.1 § 2.4 3.6 § 1.1* 3.9 § 1.3 2.7 § 0.4
CCR1 (n D 8b) 9.9 § 0.1 2.4 § 0.8** 6.5 § 1.1 1.9 § 0.1***
amean § SEM
bwithout immunostimulant these chemokine receptors were below the level of detection in 4–5 mice
Signiﬁcant differences between IVES treatment with Ty21a and no IVES treatment following an unpaired t-test are shown by *P < 0.05, **P < 0.01, and
***P < 0.001.
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Preparation of murine cells
Mice were sacrificed by CO2 inhalation and the spleen and
bladder were harvested. Single-cell suspensions were obtained as
previously described.45 Briefly, spleno-
cytes were obtained by mechanical dis-
sociation, whereas the bladders were
minced and digested stepwise with
0.5 mg/mL thermolysin (Roche) and
1 mg/mL collagenase/dispase (Roche).3
Bone marrow-derived dendritic cells
(BMDCs) were isolated using bone
marrow cells collected from tibias and
femurs of female C57BL/6 mice and
cultured in the presence of 150 U/mL
recombinant granulocyte-macrophage-
colony stimulating-factor (R and D
Systems).2
IFN-g ELISPOT assay
IFN-g ELISPOT assays were per-
formed as described45 using Multi-
screen-HA 96-well plates (MAHA
S4510, Millipore) anti–IFN-g mono-
clonal antibody (R4-6A2, Beckton
Dickinson PharMingen), biotinylated
anti–IFN-g monoclonal antibody
(XMG1.2, Beckton Dickinson Phar-
Mingen), and Streptavidin-AP (Roche).
In brief, 3 £ 104 BMDCs/well, used as
antigen-presenting cells, were incubated
for 1 h in duplicate with 1 mg/mL of
H-2Db restricted E749–57 peptide or
medium alone (control wells) before
addition of 1 £ 105 bladder cells and
incubation for 16–24 h. E7-specific
responses were defined as the number of
IFN-g spots/105cells in the E7-stimulated wells minus the num-
ber of IFN-g spots/105 cells in the control wells (<3 spots/well).
Figure 5. IVES Ty21a immunostimulation
after immunization signiﬁcantly improved
bladder tumor regression and mouse sur-
vival. Eight groups of 8–10 tumor-bearing
mice were either left untreated (black trian-
gles) or received IVES Ty21a (black asterisk,
by 3 instillations in A or 1 instillation in B),
or s.c. E7 vaccine alone (white diamonds) or
followed by Ty21a (black squares, 3 doses
in A and 1 dose in B). Mouse survival curves
are shown for each treatment (A and B).
Signiﬁcant differences in mouse survival
between each treatment and the control
are indicated by *P < 0.017, **P < 0.003,
and ***P < 0.0003 following adjusted log-
rank test. Data from both tumor protection
assays were compiled and survival at day
110 is shown in (C). Signiﬁcant differences
between groups are indicated by *P < 0.05,
***P < 0.001, and **** P < 0.0001 following
x2 test.
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Tetramer and T-cell labeling
T-cell staining was performed as previously described2 using
phycoerythrin (PE)-conjugated E749–57 and L1165–173 (as a con-
trol) H-2Db-restricted tetramers (TetE7 and TetL1, respectively,
from TC-Metrix), allophycocyanine (APC)-labeled CD8a (clone
53–6.7) and fluorescein isothiocyanate (FITC)-labeled CD4
(clone RM4-5) (both from eBioscience). TetE7CCD8C T cell
percentages among total cells were calculated after subtraction of
the background measured with control TetL1 (<5 events/blad-
der). Staining for chemokine receptors and ESL was performed
using a 10-color flow cytometry protocol as previously
described.9 The monoclonal anti-mouse antibodies used were:
PE/TXRD-anti-CD45/LCA (I3/2.3), PerCPCy5.5-anti-CD3
(17A2), AlexaFluor700-anti-CD4 (GK1.5), AlexaFluor488-anti-
CCR5 (HM-CCR5), PE-Cy7-anti-CXCR3 (CXCR3-173), PE-
Cy7-anti-C5aR (20/70) (Biolegend); APC-, PE/TXRD- or PE-
Cy7-anti-CD8a (53–6.7, eBioscience); APC-anti-CXCR2
(242216), R and D Systems); PerCPCy5.5-anti CCR1 (C-20,
Santa Cruz Biotechnology). For ESL staining, cells were incu-
bated with 2 mg of E-selectin/human IgG-Fc chimera (R and D
Systems) and detected with an AlexaFluor647-anti-human IgG
Fcg¡specific antibody (Jackson Immunoresearch). Dead cells
were excluded by a Live/Dead Fixable Aqua Dead Cell staining
kit (Invitrogen, Life Technologies).
Cell acquisition and analysis were performed using FACS Cal-
ibur (BD Biosciences) or Gallios Flow Cytometer (Beckman
Coulter) and CellQuest Pro software Version 4.0.1 (BD
Biosciences) or FlowJo software (Tree Star), respectively.
Orthotopic bladder tumor model
TC-1 cells are primary mouse lung epithelial cells that were
transduced with retroviral vectors expressing the oncogenes
HaRas and HPV16 E6 and E7.46 TC-1 cells expressing luciferase
were then generated by lentiviral infection.47 Bladder tumors
were established as previously described.3 Briefly, deeply anesthe-
tized mice were instilled with 2.5 £ 105 TC-1–luc cells by ure-
thral catheterization. Tumor growth was monitored by
bioluminescence 15 minutes after intraperitoneal injection of D-
luciferin (Promega; 150 mg/g of body weight) in the Xenogen
imaging system (Xenogen/IVIS Caliper Life Science, kindly pro-
vided by the cellular imaging facility, CIF/UNIL, Lausanne,
Switzerland).
Chemokine array
Bladders were recovered 24 h after IVES immunostimulation
with PBS, CpG, or Ty21a alone, or 5 d after E7 vaccination for
Ty21a, and homogenized in 500 mL PBS with protease inhibi-
tors (10 mg/mL aprotinin from bovine lung, 10 mg/mL leupep-
tin hemisulfate salt, and 10 mg/mL pepstatin A; all from Sigma-
Aldrich). TritonX-100 (final concentration 1%, Sigma-Aldrich)
was added after homogenization, and after 2 freeze-thaw cycles
the samples were centrifuged at 10,000 g for 5 min to remove
debris. Protein concentration was assessed using the BCA protein
assay (Thermo Scientific). Chemokines were detected using the
Proteome Profiler Array: Mouse Chemokine Array kit (R and D
Systems), according to the manufacturer’s instructions. Briefly,
150 mg of protein (pooled from 3 bladders, 50 mg each) was
used for the assay. Detection of chemokine levels was performed
using ImageJ software (NIH) and expressed as mean pixel den-
sity. Significant detection was determined as greater than the
mean C 3 SD of pixel density of negative spots. Differences in
the increased chemokine levels between the different conditions
were considered significant when greater than or equal to the
99% confidence interval of the mean fold increases examined.
Statistical analysis
Statistical analyses were performed using Prism 5.00 for Win-
dows (GraphPad software). Single comparisons were performed
by the Mann-Whitney test or by Student t test after log10 nor-
malization. Multiple comparisons were performed using one-way
ANOVA and the Tukey Multiple Comparison Test. Other statis-
tical tests are indicated in the text or figure legends.
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